Clinical Trial Update: Efficacy and Safety Study of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ABI-007 (nab-paclitaxel) plus capecitabine as first-line chemotherapy for advanced gastric cancer, with an efficacy and safety update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma

Drugs mentioned

• ABI-007 (nab-paclitaxel)
• Capecitabine (capecitabine)

Snippet

Sponsor: Yanqiao Zhang | Conditions: Gastric Adenocarcinoma | Phase 2 | Status: UNKNOWN